Efficacy of Oral Administration of Sodium Thiosulfate and Glycine in a Large, Swine Model of Oral Cyanide Toxicity - 23/08/19
, Tara B. Hendry-Hofer, BSN b, Alyssa E. Witeof, BS b, Sari B. Mahon, PhD c, Matthew Brenner, MD c, d, Gerry R. Boss, MD e, Vikhyat S. Bebarta, MD a, bAbstract |
Study objective |
Cyanide is a deadly poison, particularly with oral exposure, in which larger doses can occur before any symptoms develop. Multiple governmental agencies highlight oral cyanide as an agent that can be used in a terrorist attack because it can be easily weaponized and is readily available. Currently, there are no Food and Drug Administration–approved antidotes specifically for oral cyanide. An oral countermeasure that can neutralize and prevent absorption of cyanide from the gastrointestinal tract after oral exposure is needed. The objective of this study is to determine if the combination of glycine and sodium thiosulfate administered orally is effective in reducing mortality in a large, swine model of oral cyanide toxicity.
Methods |
Nine swine (45 to 55 kg) were instrumented, sedated, and stabilized. Potassium cyanide (at 8 mg/kg) in saline solution was delivered as a onetime bolus through an orogastric tube. Three minutes after cyanide administration, animals that were randomized to the treatment group received sodium thiosulfate (508.2 mg/kg, 3.25-M solution) and glycine (30 mg/kg, 3.5-M solution) through an orogastric tube. Survival at 60 minutes was the primary outcome. We compared survival between groups by log-rank Mantel-Cox analysis and trended laboratory results and vital signs.
Results |
At baseline and treatment, all animals were similar. Survival at 60 minutes was 100% in treated animals compared with 0% in the control group (P=.003). By the study end, defined as death or 60 minutes after cyanide administration, there was a significant difference in the lactate concentration between the treatment and control groups (control 9.43 mmol/L [SD 4.08]; treatment 1.66 mmol/L [SD 0.82]; difference between means 7.69 mmol/L [SD 2.07]; 95% confidence interval difference –14.05 to –1.32). Mean arterial pressure was significantly different between the treatment and control groups at study end (control 26 mm Hg [SD 6.7]; treatment 81 mm Hg [SD 14]; difference between means 55.2 mm Hg [SD 7.1]; 95% confidence interval difference 37.8 to 72.6). pH and oxygen saturation were also significantly different between the treatment and control groups at study end.
Conclusion |
The combination of oral sodium thiosulfate and glycine significantly improved survival and physiologic parameters in a large-animal model of oral cyanide toxicity.
Le texte complet de cet article est disponible en PDF.Plan
| Please see page 424 for the Editor’s Capsule Summary of this article. |
|
| Supervising editor: Matthew D. Sztajnkrycer, MD, PhD. Specific detailed information about possible conflict of interest for individual editors is available at editors. |
|
| Author contributions: PCN was involved in obtaining research funding and supervising conduct of experiments. PCN, TBH-H, AEW, and VSB were involved in study design. PCN, TBH-H, AEW, MB, GB, VSB, and SM were involved in data collection and analysis. TBH-H, AEW, MB, GB, VSB, and SM were involved in protocol development. All authors were involved in writing and editing the article and approve the submitted version. PCN takes responsibility for the paper as a whole. |
|
| All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. |
|
| Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Funding for this study was provided by the American Academy of Clinical Toxicology 2018 Junior Investigator Award. |
|
| The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the US Air Force, Department of Defense, or the US government. |
|
| Readers: click on the link to go directly to a survey in which you can provide 6TNVNT8 to Annals on this particular article. |
Vol 74 - N° 3
P. 423-429 - septembre 2019 Retour au numéro
Article précédent
- Managing the Out-of-Hospital Extraglottic Airway Device
- Darren Braude, Michael Steuerwald, Trent Wray, Richard Galgon
- Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder
- Reid H. Phillips, Matthew Salzman, Rachel Haroz, Rachel Rafeq, Anthony J. Mazzarelli, Alexis Pelletier-Bui
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?